The Department of Health in Abu Dhabi, the regulator of the health care sector in the Emirate of Abu Dhabi, has provided three drugs to treat and prevent the “Covid-19” virus
The Department of Health in Abu Dhabi, the regulator of the health care sector in the Emirate of Abu Dhabi, has provided three drugs to treat and prevent the “Covid-19” virus, as part of its continuous efforts to ensure the health and safety of members of society, which qualified it to be at the forefront of the classification of leading cities around the world in Response to the COVID-19 pandemic.
In detail, the Abu Dhabi Department of Health confirmed its continuation of its exceptional response and leadership, as part of global efforts to combat and contain the "Covid-19" pandemic, to improve health care services in the emirate, by strengthening important global partnerships, which contribute to attracting and using the latest innovations and treatment solutions that supplement the efforts of The outstanding response to the pandemic in Abu Dhabi, and contributes to ensuring the health and safety of community members.
The department indicated that it has provided the drug "Roche" (caserifimab and imdivimab), which works to prevent corona virus, and treat patients with mild and moderate cases in the emirate, pointing out that the drug "Roche" consists of a mixture of antibodies consisting of the drugs "caserifimab" and "Roche". "Imdivimab", is able to treat people infected with the virus and prevent disease.
The department provided the drug "AstraZeneca AZD7442", thus making the UAE, and after obtaining the necessary use approvals, among the first countries to use this drug that generates antibodies for patients with weak immunity.
In addition to the drugs “Cazerivimab”, “Emdivimab”, and AstraZeneca (AZD7442), Abu Dhabi was the first city in the world to receive last June a shipment of the drug “Sutrovimab”, which is intended to treat infection with the “Covid-19” virus, becoming the first city in the world to receive The new treatment.
Sotrovimab is the latest drug in the world to treat certain cases of people infected with the “Covid-19” virus, and it contains monoclonal antibodies, given intravenously, and can be used to treat adults and children over 12 years of age, who meet certain criteria and are at risk. The development of severe symptoms of "Covid-19" in them, according to the protocols developed by the National Scientific Committee, where studies have shown that the drug prevents the development of the disease to severe cases or death in more than 85% of early treatment cases.
Read also :